ATOS logo

ATOSSA THERAPEUTICS INC

ATOSNASDAQ
🏆 #4583 by market capUS Equity
$2.36—
Last available close · quote unavailable
🔔
Track ATOS
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▼ 13.6%
14d▼ 11.3%
30d▲ 19.8%
ytd▼ 73.1%
1y▼ 82.0%
🏦Market Cap
$24M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
62.5%
High
💵FCF Margin
—
⚖️P/S Ratio
147.8x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$1.70 – $14.85
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
10.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
147.8x
EPS (TTM)
$-4.34
Dividend Yield
—
Dilution (1yr)
+2.0%
ATOS logo

ATOSSA THERAPEUTICS INC

ATOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$37M▲ +34.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▲ +41.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.6M▲ +2.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$41M▼ −$30M YoY
StockOtter · stockotter.space

About ATOSSA THERAPEUTICS INC

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.